Bradshaw, E. M. et al. CD33 Alzheimer’s disease locus: altered monocyte function and amyloid biology. Nat. Neurosci. 16, 848–850 (2013).
Deming, Y. et al. The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer’s disease risk. Sci. Transl. Med. 11, eaau2291 (2019).
Griciuc, A. & Tanzi, R. E. The role of innate immune genes in Alzheimer’s disease. Curr. Opin. Neurol. 34, 228–236 (2021).
Yang, X. et al. Functional characterization of Alzheimer’s disease genetic variants in microglia. Nat. Genet. 55, 1735–1744 (2023).
Stephenson, J., Nutma, E., van der Valk, P. & Amor, S. Inflammation in CNS neurodegenerative diseases. Immunology 154, 204–219 (2018).
Ovadya, Y. et al. Impaired immune surveillance accelerates accumulation of senescent cells and aging. Nat. Commun. 9, 5435 (2018).
Knuesel, I. et al. Maternal immune activation and abnormal brain development across CNS disorders. Nat. Rev. Neurol. 10, 643–660 (2014).
Mattei, D. et al. Maternal immune activation results in complex microglial transcriptome signature in the adult offspring that is reversed by minocycline treatment. Transl. Psychiatry 7, e1120 (2017).
Bilbo, S. D. & Schwarz, J. M. The immune system and developmental programming of brain and behavior. Front. Neuroendocrinol. 33, 267–286 (2012).
Tanabe, S. & Yamashita, T. B-1a lymphocytes promote oligodendrogenesis during brain development. Nat. Neurosci. 21, 506–516 (2018).
Pasciuto, E. et al. Microglia require CD4 T cells to complete the fetal-to-adult transition. Cell 182, 625–640 e624 (2020).
Ziv, Y. et al. Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood. Nat. Neurosci. 9, 268–275 (2006).
Wolf, S. A. et al. CD4-positive T lymphocytes provide a neuroimmunological link in the control of adult hippocampal neurogenesis. J. Immunol. 182, 3979–3984 (2009).
Filiano, A. J. et al. Unexpected role of interferon-γ in regulating neuronal connectivity and social behaviour. Nature 535, 425–429 (2016).
Pereira, L., Medina, R., Baena, M., Planas, A. M. & Pozas, E. IFN-γ regulates proliferation and neuronal differentiation by STAT1 in adult SVZ niche. Front. Cell Neurosci. 9, 270 (2015).
Yang, H. S. et al. Plasma IL-12/IFN-γ axis predicts cognitive trajectories in cognitively unimpaired older adults. Alzheimers Dement. 18, 645–653 (2022).
Loayza, M. et al. Maternal immune activation alters fetal and neonatal microglia phenotype and disrupts neurogenesis in mice. Pediatr. Res. 93, 1216–1225 (2023).
Garay, P. A., Hsiao, E. Y., Patterson, P. H. & McAllister, A. K. Maternal immune activation causes age- and region-specific changes in brain cytokines in offspring throughout development. Brain Behav. Immun. 31, 54–68 (2013).
Lyra, E. S. N. M. et al. Pro-inflammatory interleukin-6 signaling links cognitive impairments and peripheral metabolic alterations in Alzheimer’s disease. Transl. Psychiatry 11, 251 (2021).
Shaftel, S. S., Griffin, W. S. & O’Banion, M. K. The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. J. Neuroinflammation 5, 7 (2008).
Brigas, H. C. et al. IL-17 triggers the onset of cognitive and synaptic deficits in early stages of Alzheimer’s disease. Cell Rep. 36, 109574 (2021).
Tanaka, S. et al. Lipopolysaccharide-induced microglial activation induces learning and memory deficits without neuronal cell death in rats. J. Neurosci. Res. 83, 557–566 (2006).
Alves de Lima, K. et al. Meningeal γΔ T cells regulate anxiety-like behavior via IL-17a signaling in neurons. Nat. Immunol. 21, 1421–1429 (2020).
Ribeiro, M. et al. Meningeal γΔ T cell-derived IL-17 controls synaptic plasticity and short-term memory. Sci. Immunol. 4, eaay5199 (2019).
Yin, Z. et al. Identification of a protective microglial state mediated by miR-155 and interferon-γ signaling in a mouse model of Alzheimer’s disease. Nat. Neurosci. 26, 1196–1207 (2023).
[No authors listed]. Alzheimer’s disease facts and figures. Alzheimers Dement. 20, 3708–3821 (2024).
Han, S., Georgiev, P., Ringel, A. E., Sharpe, A. H. & Haigis, M. C. Age-associated remodeling of T cell immunity and metabolism. Cell Metab. 35, 36–55 (2023).
Bowirrat, A. Immunosenescence and aging: neuroinflammation is a prominent feature of Alzheimer’s disease and is a likely contributor to neurodegenerative disease pathogenesis. J. Pers. Med. 12, 1817 (2022).
Basurco, L., Abellanas, M. A., Purnapatre, M., Antonello, P. & Schwartz, M. Chronological versus immunological aging: immune rejuvenation to arrest cognitive decline. Neuron 113, 140–153 (2025).
Yousefzadeh, M. J. et al. An aged immune system drives senescence and ageing of solid organs. Nature 594, 100–105 (2021).
Groh, J. et al. Accumulation of cytotoxic T cells in the aged CNS leads to axon degeneration and contributes to cognitive and motor decline. Nat. Aging 1, 357–367 (2021).
Sun, P. Y. et al. Rejuvenation of peripheral immune cells attenuates Alzheimer’s disease-like pathologies and behavioral deficits in a mouse model. Sci. Adv. 10, eadl1123 (2024).
Das, M. M. et al. Young bone marrow transplantation preserves learning and memory in old mice. Commun. Biol. 2, 73 (2019).
Borst, K., Dumas, A. A. & Prinz, M. Microglia: immune and non-immune functions. Immunity 54, 2194–2208 (2021).
Kierdorf, K. et al. Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways. Nat. Neurosci. 16, 273–280 (2013).
Ginhoux, F. et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 330, 841–845 (2010).
Schulz, C. et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science 336, 86–90 (2012).
Fu, R., Shen, Q., Xu, P., Luo, J. J. & Tang, Y. Phagocytosis of microglia in the central nervous system diseases. Mol. Neurobiol. 49, 1422–1434 (2014).
Neumann, H., Kotter, M. R. & Franklin, R. J. Debris clearance by microglia: an essential link between degeneration and regeneration. Brain 132, 288–295 (2009).
Heneka, M. T. et al. Neuroinflammation in Alzheimer disease. Nat. Rev. Immunol. 25, 321–352 (2025).
Krasemann, S. et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity 47, 566–581 e569 (2017).
Keren-Shaul, H. et al. A unique microglia type associated with restricting development of Alzheimer’s disease. Cell 169, 1276–1290 e1217 (2017).
Butovsky, O. et al. Identification of a unique TGF-β-dependent molecular and functional signature in microglia. Nat. Neurosci. 17, 131–143 (2014).
Sala Frigerio, C. et al. The major risk factors for Alzheimer’s disease: age, sex, and genes modulate the microglia response to Aβ plaques. Cell Rep. 27, 1293–1306 e1296 (2019).
Sierksma, A. et al. Novel Alzheimer risk genes determine the microglia response to amyloid-β but not to TAU pathology. EMBO Mol. Med. 12, e10606 (2020).
Millet, A., Ledo, J. H. & Tavazoie, S. F. An exhausted-like microglial population accumulates in aged and APOE4 genotype Alzheimer’s brains. Immunity 57, 153–170 e156 (2024).
Rachmian, N. et al. Identification of senescent, TREM2-expressing microglia in aging and Alzheimer’s disease model mouse brain. Nat. Neurosci. 27, 1116–1124 (2024).
Silvin, A. et al. Dual ontogeny of disease-associated microglia and disease inflammatory macrophages in aging and neurodegeneration. Immunity 55, 1448–1465 e1446 (2022).
Yin, Z. et al. APOE4 impairs the microglial response in Alzheimer’s disease by inducing TGFβ-mediated checkpoints. Nat. Immunol. 24, 1839–1853 (2023).
Rosenzweig, N. et al. Sex-dependent APOE4 neutrophil–microglia interactions drive cognitive impairment in Alzheimer’s disease. Nat. Med. 30, 2990–3003 (2024).
Brandao, W. et al. Inhaled xenon modulates microglia and ameliorates disease in mouse models of amyloidosis and tauopathy. Sci. Transl. Med. 17, eadk3690 (2025).
Kiani Shabestari, S. et al. Absence of microglia promotes diverse pathologies and early lethality in Alzheimer’s disease mice. Cell Rep. 39, 110961 (2022).
Kimura, K. et al. Immune checkpoint TIM-3 regulates microglia and Alzheimer’s disease. Nature 641, 718–731 (2025).
Ennerfelt, H. et al. SYK coordinates neuroprotective microglial responses in neurodegenerative disease. Cell 185, 4135–4152 e4122 (2022).
Spani, C. et al. Reduced β-amyloid pathology in an APP transgenic mouse model of Alzheimer’s disease lacking functional B and T cells. Acta Neuropathol. Commun. 3, 71 (2015).
Baruch, K. et al. Breaking immune tolerance by targeting Foxp3+ regulatory T cells mitigates Alzheimer’s disease pathology. Nat. Commun. 6, 7967 (2015).
Baruch, K. et al. PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer’s disease. Nat. Med. 22, 135–137 (2016).
Mittal, K. et al. CD4 T cells induce a subset of MHCII-expressing microglia that attenuates Alzheimer pathology. iScience 16, 298–311 (2019).
He, Z. et al. Intraperitoneal injection of IFN-γ restores microglial autophagy, promotes amyloid-β clearance and improves cognition in APP/PS1 mice. Cell Death Dis. 11, 440 (2020).
Fisher, Y., Nemirovsky, A., Baron, R. & Monsonego, A. T cells specifically targeted to amyloid plaques enhance plaque clearance in a mouse model of Alzheimer’s disease. PLoS ONE 5, e10830 (2010).
Su, W. et al. CXCR6 orchestrates brain CD8+ T cell residency and limits mouse Alzheimer’s disease pathology. Nat. Immunol. 24, 1735–1747 (2023).
Dansokho, C. et al. Regulatory T cells delay disease progression in Alzheimer-like pathology. Brain 139, 1237–1251 (2016).
Stym-Popper, G. et al. Regulatory T cells decrease C3-positive reactive astrocytes in Alzheimer-like pathology. J. Neuroinflammation 20, 64 (2023).
Laurent, C. et al. Hippocampal T cell infiltration promotes neuroinflammation and cognitive decline in a mouse model of tauopathy. Brain 140, 184–200 (2017).
Chen, X. et al. Microglia-mediated T cell infiltration drives neurodegeneration in tauopathy. Nature 615, 668–677 (2023).
Kaya, T. et al. CD8+ T cells induce interferon-responsive oligodendrocytes and microglia in white matter aging. Nat. Neurosci. 25, 1446–1457 (2022).
Kedia, S. et al. T cell-mediated microglial activation triggers myelin pathology in a mouse model of amyloidosis. Nat. Neurosci. 27, 1468–1474 (2024).
Terrabuio, E. et al. CD103−CD8+ T cells promote neurotoxic inflammation in Alzheimer’s disease via granzyme K-PAR-1 signaling. Nat. Commun. 16, 8372 (2025).
Peralta Ramos, J. M. et al. Targeting CD38 immunometabolic checkpoint improves metabolic fitness and cognition in a mouse model of Alzheimer’s disease. Nat. Commun. 16, 3736 (2025).
Jorfi, M. et al. Infiltrating CD8+ T cells exacerbate Alzheimer’s disease pathology in a 3D human neuroimmune axis model. Nat. Neurosci. 26, 1489–1504 (2023).
Gate, D. et al. Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer’s disease. Nature 577, 399–404 (2020).
Bongioanni, P., Boccardi, B., Borgna, M., Castagna, M. & Mondino, C. T-cell interferon γ binding in patients with dementia of the Alzheimer type. Arch. Neurol. 54, 457–462 (1997).
Grayson, J. M. et al. T cell exhaustion is associated with cognitive status and amyloid accumulation in Alzheimer’s disease. Sci. Rep. 13, 15779 (2023).
Park, J. C. et al. Association of B cell profile and receptor repertoire with the progression of Alzheimer’s disease. Cell Rep. 40, 111391 (2022).
Kim, K. et al. Therapeutic B-cell depletion reverses progression of Alzheimer’s disease. Nat. Commun. 12, 2185 (2021).
Feng, W. et al. B lymphocytes ameliorate Alzheimer’s disease-like neuropathology via interleukin-35. Brain Behav. Immun. 108, 16–31 (2023).
Li, X., Fang, P., Yang, W. Y., Wang, H. & Yang, X. IL-35, as a newly proposed homeostasis-associated molecular pattern, plays three major functions including anti-inflammatory initiator, effector, and blocker in cardiovascular diseases. Cytokine 122, 154076 (2019).
Sollvander, S. et al. Increased number of plasma B cells producing autoantibodies against Aβ42 protofibrils in Alzheimer’s disease. J. Alzheimers Dis. 48, 63–72 (2015).
Zhang, Y., Chen, H., Li, R., Sterling, K. & Song, W. Amyloid β-based therapy for Alzheimer’s disease: challenges, successes and future. Signal. Transduct. Target. Ther. 8, 248 (2023).
Monsonego, A. et al. Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer disease. J. Clin. Invest. 112, 415–422 (2003).
Gaskin, F., Finley, J., Fang, Q., Xu, S. & Fu, S. M. Human antibodies reactive with β-amyloid protein in Alzheimer’s disease. J. Exp. Med. 177, 1181–1186 (1993).
Matsuo, K. et al. Vaccine efficacy of transcutaneous immunization with amyloid β using a dissolving microneedle array in a mouse model of Alzheimer’s disease. J. Neuroimmunol. 266, 1–11 (2014).
Toly-Ndour, C. et al. MHC-independent genetic factors control the magnitude of CD4+ T cell responses to amyloid-β peptide in mice through regulatory T cell-mediated inhibition. J. Immunol. 187, 4492–4500 (2011).
Rosset, M. B., Lui, G., Dansokho, C., Chaigneau, T. & Dorothee, G. Vaccine-induced Aβ-specific CD8+ T cells do not trigger autoimmune neuroinflammation in a murine model of Alzheimer’s disease. J. Neuroinflammation 12, 95 (2015).
Theriault, P., ElAli, A. & Rivest, S. The dynamics of monocytes and microglia in Alzheimer’s disease. Alzheimers Res. Ther. 7, 41 (2015).
Davis, J. B., McMurray, H. F. & Schubert, D. The amyloid β-protein of Alzheimer’s disease is chemotactic for mononuclear phagocytes. Biochem. Biophys. Res. Commun. 189, 1096–1100 (1992).
Zaghi, J. et al. Alzheimer disease macrophages shuttle amyloid-β from neurons to vessels, contributing to amyloid angiopathy. Acta Neuropathol. 117, 111–124 (2009).
Qosa, H. et al. Differences in amyloid-β clearance across mouse and human blood–brain barrier models: kinetic analysis and mechanistic modeling. Neuropharmacology 79, 668–678 (2014).
Huang, X. et al. Clearance and transport of amyloid β by peripheral monocytes correlate with Alzheimer’s disease progression. Nat. Commun. 15, 7998 (2024).
Yan, P. et al. Peripheral monocyte-derived cells counter amyloid plaque pathogenesis in a mouse model of Alzheimer’s disease. J. Clin. Invest. 132, e152565 (2022).
Munoz-Castro, C. et al. Monocyte-derived cells invade brain parenchyma and amyloid plaques in human Alzheimer’s disease hippocampus. Acta Neuropathol. Commun. 11, 31 (2023).
Simard, A. R., Soulet, D., Gowing, G., Julien, J. P. & Rivest, S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer’s disease. Neuron 49, 489–502 (2006).
Prokop, S. et al. Impact of peripheral myeloid cells on amyloid-β pathology in Alzheimer’s disease-like mice. J. Exp. Med. 212, 1811–1818 (2015).
Varvel, N. H. et al. Replacement of brain-resident myeloid cells does not alter cerebral amyloid-β deposition in mouse models of Alzheimer’s disease. J. Exp. Med. 212, 1803–1809 (2015).
Fiala, M. et al. Ineffective phagocytosis of amyloid-β by macrophages of Alzheimer’s disease patients. J. Alzheimers Dis. 7, 221–232 (2005).
Chen, S. H. et al. Amyloid-β uptake by blood monocytes is reduced with ageing and Alzheimer’s disease. Transl. Psychiatry 10, 423 (2020).
Gu, B. J. et al. Innate phagocytosis by peripheral blood monocytes is altered in Alzheimer’s disease. Acta Neuropathol. 132, 377–389 (2016).
Drieu, A. et al. Parenchymal border macrophages regulate the flow dynamics of the cerebrospinal fluid. Nature 611, 585–593 (2022).
Jairani, P. S. et al. Apolipoprotein E polymorphism and oxidative stress in peripheral blood-derived macrophage-mediated amyloid-β phagocytosis in alzheimer’s disease patients. Cell Mol. Neurobiol. 39, 355–369 (2019).
Kim, T. et al. Human LilrB2 is a β-amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimer’s model. Science 341, 1399–1404 (2013).
Zhao, Y. et al. TREM2 is a receptor for β-amyloid that mediates microglial function. Neuron 97, 1023–1031 e1027 (2018).
Jiang, T. et al. TREM1 facilitates microglial phagocytosis of amyloid β. Acta Neuropathol. 132, 667–683 (2016).
Bellenguez, C. et al. New insights into the genetic etiology of Alzheimer’s disease and related dementias. Nat. Genet. 54, 412–436 (2022).
Yazawa, H. et al. β Amyloid peptide (Aβ42) is internalized via the G-protein-coupled receptor FPRL1 and forms fibrillar aggregates in macrophages. FASEB J. 15, 2454–2462 (2001).
Ying, G. et al. Humanin, a newly identified neuroprotective factor, uses the G protein-coupled formylpeptide receptor-like-1 as a functional receptor. J. Immunol. 172, 7078–7085 (2004).
El Khoury, J. B. et al. CD36 mediates the innate host response to β-amyloid. J. Exp. Med. 197, 1657–1666 (2003).
Uekawa, K. et al. Border-associated macrophages promote cerebral amyloid angiopathy and cognitive impairment through vascular oxidative stress. Mol. Neurodegener. 18, 73 (2023).
Li, Q. et al. Monocytes release cystatin F dimer to associate with Aβ and aggravate amyloid pathology and cognitive deficits in Alzheimer’s disease. J. Neuroinflammation 21, 125 (2024).
Raj, T. et al. CD33: increased inclusion of exon 2 implicates the Ig V-set domain in Alzheimer’s disease susceptibility. Hum. Mol. Genet. 23, 2729–2736 (2014).
Juul-Madsen, K. et al. Amyloid-β aggregates activate peripheral monocytes in mild cognitive impairment. Nat. Commun. 15, 1224 (2024).
Panayiotou, E. et al. C5aR agonist enhances phagocytosis of fibrillar and non-fibrillar Aβ amyloid and preserves memory in a mouse model of familial Alzheimer’s disease. PLoS One 14, e0225417 (2019).
Kim, A. B. et al. Chimeric antigen receptor macrophages target and resorb amyloid plaques. JCI Insight 9, e175015 (2024).
Colella, P. et al. CNS-wide repopulation by hematopoietic-derived microglia-like cells corrects progranulin deficiency in mice. Nat. Commun. 15, 5654 (2024).
Cronk, J. C. et al. Peripherally derived macrophages can engraft the brain independent of irradiation and maintain an identity distinct from microglia. J. Exp. Med. 215, 1627–1647 (2018).
Bastos, J. et al. Monocytes can efficiently replace all brain macrophages and fetal liver monocytes can generate bona fide SALL1+ microglia. Immunity 58, 1269–1288 e1212 (2025).
Aisenberg, W. H. et al. Direct microglia replacement reveals pathologic and therapeutic contributions of brain macrophages to a monogenic neurological disease. Immunity 58, 1254–1268 e1259 (2025).
Liu, Z. et al. Fate mapping via Ms4a3-expression history traces monocyte-derived cells. Cell 178, 1509–1525 e1519 (2019).
McKinsey, G. L. et al. A new genetic strategy for targeting microglia in development and disease. eLife 9, e54590 (2020).
Chen, H. R. et al. Fate mapping via CCR2-CreER mice reveals monocyte-to-microglia transition in development and neonatal stroke. Sci. Adv. 6, eabb2119 (2020).
Attems, J. & Jellinger, K. A. The overlap between vascular disease and Alzheimer’s disease — lessons from pathology. BMC Med. 12, 206 (2014).
Lehmann, M. L. et al. CCR2 monocytes repair cerebrovascular damage caused by chronic social defeat stress. Brain Behav. Immun. 101, 346–358 (2022).
El Khoury, J. et al. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat. Med. 13, 432–438 (2007).
Naert, G. & Rivest, S. CC chemokine receptor 2 deficiency aggravates cognitive impairments and amyloid pathology in a transgenic mouse model of Alzheimer’s disease. J. Neurosci. 31, 6208–6220 (2011).
Naert, G. & Rivest, S. Hematopoietic CC-chemokine receptor 2 (CCR2) competent cells are protective for the cognitive impairments and amyloid pathology in a transgenic mouse model of Alzheimer’s disease. Mol. Med. 18, 297–313 (2012).
Dvir-Szternfeld, R. et al. Alzheimer’s disease modification mediated by bone marrow-derived macrophages via a TREM2-independent pathway in mouse model of amyloidosis. Nat. Aging 2, 60–73 (2022).
Wang, L. et al. CCR2+ monocytes replenish border-associated macrophages in the diseased mouse brain. Cell Rep. 43, 114120 (2024).
Anfray, A. et al. A cell-autonomous role for border-associated macrophages in ApoE4 neurovascular dysfunction and susceptibility to white matter injury. Nat. Neurosci. 27, 2138–2151 (2024).
Abellanas, M. A., Purnapatre, M., Burgaletto, C. & Schwartz, M. Monocyte-derived macrophages act as reinforcements when microglia fall short in Alzheimer’s disease. Nat. Neurosci. 28, 436–445 (2025).
Zenaro, E. et al. Neutrophils promote Alzheimer’s disease-like pathology and cognitive decline via LFA-1 integrin. Nat. Med. 21, 880–886 (2015).
Baik, S. H. et al. Migration of neutrophils targeting amyloid plaques in Alzheimer’s disease mouse model. Neurobiol. Aging 35, 1286–1292 (2014).
Kong, Y. et al. PET imaging of neutrophils infiltration in Alzheimer’s disease transgenic mice. Front. Neurol. 11, 523798 (2020).
Smyth, L. C. D. et al. Neutrophil–vascular interactions drive myeloperoxidase accumulation in the brain in Alzheimer’s disease. Acta Neuropathol. Commun. 10, 38 (2022).
Dong, Y. et al. Neutrophil hyperactivation correlates with Alzheimer’s disease progression. Ann. Neurol. 83, 387–405 (2018).
Cruz Hernandez, J. C. et al. Neutrophil adhesion in brain capillaries reduces cortical blood flow and impairs memory function in Alzheimer’s disease mouse models. Nat. Neurosci. 22, 413–420 (2019).
Korn, T. et al. IL-21 initiates an alternative pathway to induce proinflammatory TH17 cells. Nature 448, 484–487 (2007).
Gruel, R. et al. S100A8-enriched microglia populate the brain of tau-seeded and accelerated aging mice. Aging Cell 23, e14120 (2024).
Wilson, E. N. et al. TREM1 disrupts myeloid bioenergetics and cognitive function in aging and Alzheimer disease mouse models. Nat. Neurosci. 27, 873–885 (2024).
Hao, W. et al. Modulation of Alzheimer’s disease brain pathology in mice by gut bacterial depletion: the role of IL-17a. Gut Microbes 16, 2363014 (2024).
Kim, M. S. et al. Transfer of a healthy microbiota reduces amyloid and tau pathology in an Alzheimer’s disease animal model. Gut 69, 283–294 (2020).
Seo, D. O. et al. ApoE isoform- and microbiota-dependent progression of neurodegeneration in a mouse model of tauopathy. Science 379, eadd1236 (2023).
Qi, C. et al. Alzheimer’s disease alters the transcriptomic profile of natural killer cells at single-cell resolution. Front. Immunol. 13, 1004885 (2022).
Zuniga, C. H. et al. Treatment of Alzheimer’s disease subjects with expanded non-genetically modified autologous natural killer cells (SNK01): a phase I study. Alzheimers Res. Ther. 17, 40 (2025).
Zhang, Y. et al. Depletion of NK cells improves cognitive function in the alzheimer disease mouse model. J. Immunol. 205, 502–510 (2020).
Deelen, J. et al. A meta-analysis of genome-wide association studies identifies multiple longevity genes. Nat. Commun. 10, 3669 (2019).
Lv, S. et al. ApoE4 exacerbates the senescence of hippocampal neurons and spatial cognitive impairment by downregulating acetyl-CoA level. Aging Cell 22, e13932 (2023).
Haney, M. S. et al. APOE4/4 is linked to damaging lipid droplets in Alzheimer’s disease microglia. Nature 628, 154–161 (2024).
Yin, H. et al. Loss of the m6A methyltransferase METTL3 in monocyte-derived macrophages ameliorates Alzheimer’s disease pathology in mice. PLoS Biol. 21, e3002017 (2023).
Sun, H. L. et al. The correlation of tau levels with blood monocyte count in patients with Alzheimer’s disease. J. Alzheimers Dis. 85, 1321–1328 (2022).
de la Monte, S. M. & Tong, M. Brain metabolic dysfunction at the core of Alzheimer’s disease. Biochem. Pharmacol. 88, 548–559 (2014).
Wang, W., Zhao, F., Ma, X., Perry, G. & Zhu, X. Mitochondria dysfunction in the pathogenesis of Alzheimer’s disease: recent advances. Mol. Neurodegener. 15, 30 (2020).
Phu, T. A., Ng, M., Vu, N. K., Gao, A. S. & Raffai, R. L. ApoE expression in macrophages communicates immunometabolic signaling that controls hyperlipidemia-driven hematopoiesis & inflammation via extracellular vesicles. J. Extracell. Vesicles 12, e12345 (2023).
Jaitin, D. A. et al. Lipid-associated macrophages control metabolic homeostasis in a trem2-dependent manner. Cell 178, 686–698 e614 (2019).
Podlesny-Drabiniok, A. et al. BHLHE40/41 regulate microglia and peripheral macrophage responses associated with Alzheimer’s disease and other disorders of lipid-rich tissues. Nat. Commun. 15, 2058 (2024).
Minhas, P. S. et al. Restoring metabolism of myeloid cells reverses cognitive decline in ageing. Nature 590, 122–128 (2021).
Johansson, J. U. et al. Suppression of inflammation with conditional deletion of the prostaglandin E2 EP2 receptor in macrophages and brain microglia. J. Neurosci. 33, 16016–16032 (2013).
Replogle, J. M. et al. A TREM1 variant alters the accumulation of Alzheimer-related amyloid pathology. Ann. Neurol. 77, 469–477 (2015).
Bouchon, A., Dietrich, J. & Colonna, M. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J. Immunol. 164, 4991–4995 (2000).
Wlodarczyk, A. et al. Pathologic and protective roles for microglial subsets and bone marrow- and blood-derived myeloid cells in central nervous system inflammation. Front. Immunol. 6, 463 (2015).
Mattiola, I. et al. The macrophage tetraspan MS4A4A enhances dectin-1-dependent NK cell-mediated resistance to metastasis. Nat. Immunol. 20, 1012–1022 (2019).
Suzzi, S. et al. N-acetylneuraminic acid links immune exhaustion and accelerated memory deficit in diet-induced obese Alzheimer’s disease mouse model. Nat. Commun. 14, 1293 (2023).
Munawara, U. et al. Hyperactivation of monocytes and macrophages in MCI patients contributes to the progression of Alzheimer’s disease. Immun. Ageing 18, 29 (2021).
Young, J. J. et al. Aging gene signature of memory CD8+ T cells is associated with neurocognitive functioning in Alzheimer’s disease. Immun. Ageing 20, 71 (2023).
Le Page, A. et al. NK cells are activated in amnestic mild cognitive impairment but not in mild Alzheimer’s disease patients. J. Alzheimers Dis. 46, 93–107 (2015).
Sommerer, Y. et al. Entorhinal cortex epigenome-wide association study highlights four novel loci showing differential methylation in Alzheimer’s disease. Alzheimers Res. Ther. 15, 92 (2023).
Fransquet, P. D. et al. DNA methylation analysis of candidate genes associated with dementia in peripheral blood. Epigenomics 12, 2109–2123 (2020).
Gjoneska, E. et al. Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer’s disease. Nature 518, 365–369 (2015).
Ramakrishnan, A. et al. Epigenetic dysregulation in Alzheimer’s disease peripheral immunity. Neuron 112, 1235–1248 e1235 (2024).
Holstege, H. et al. Exome sequencing identifies rare damaging variants in ATP8B4 and ABCA1 as risk factors for Alzheimer’s disease. Nat. Genet. 54, 1786–1794 (2022).
Hu, X. et al. Meta-analysis for genome-wide association study identifies multiple variants at the BIN1 locus associated with late-onset Alzheimer’s disease. PLoS One 6, e16616 (2011).
Tiwari, V. et al. Innate immune training restores pro-reparative myeloid functions to promote remyelination in the aged central nervous system. Immunity 57, 2173–2190 e2178 (2024).
Fransquet, P. D. et al. Blood DNA methylation signatures to detect dementia prior to overt clinical symptoms. Alzheimers Dement. 12, e12056 (2020).
Silva, T. C. et al. Cross-tissue analysis of blood and brain epigenome-wide association studies in Alzheimer’s disease. Nat. Commun. 13, 4852 (2022).
Wightman, D. P. et al. A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer’s disease. Nat. Genet. 53, 1276–1282 (2021).
Sherva, R. et al. African ancestry GWAS of dementia in a large military cohort identifies significant risk loci. Mol. Psychiatry 28, 1293–1302 (2023).
Piehl, N. et al. Cerebrospinal fluid immune dysregulation during healthy brain aging and cognitive impairment. Cell 185, 5028–5039 e5013 (2022).
Kosoy, R. et al. Genetics of the human microglia regulome refines Alzheimer’s disease risk loci. Nat. Genet. 54, 1145–1154 (2022).
Ayata, P. et al. Lymphoid gene expression supports neuroprotective microglia function. Nature https://doi.org/10.1038/s41586-025-09662-z (2025).
Phongpreecha, T. et al. Single-cell peripheral immunoprofiling of Alzheimer’s and Parkinson’s diseases. Sci. Adv. 6, eabd5575 (2020).
Magno, L. et al. Alzheimer’s disease phospholipase C-γ-2 (PLCG2) protective variant is a functional hypermorph. Alzheimers Res. Ther. 11, 16 (2019).
Diks, A. M. et al. Carriers of the p.P522R variant in PLCγ2 have a slightly more responsive immune system. Mol. Neurodegener. 18, 25 (2023).
Takalo, M. et al. The Alzheimer’s disease-associated protective Plcγ2-P522R variant promotes immune functions. Mol. Neurodegener. 15, 52 (2020).
Kleineidam, L. et al. PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment. Acta Neuropathol. 139, 1025–1044 (2020).
Tsai, A. P. et al. Genetic variants of phospholipase C-γ2 alter the phenotype and function of microglia and confer differential risk for Alzheimer’s disease. Immunity 56, 2121–2136 e2126 (2023).
Tsai, A. P. et al. PLCG2 is associated with the inflammatory response and is induced by amyloid plaques in Alzheimer’s disease. Genome Med. 14, 17 (2022).
Tesi, N. et al. Cognitively healthy centenarians are genetically protected against Alzheimer’s disease. Alzheimers Dement. 20, 3864–3875 (2024).
Tesi, N. et al. Immune response and endocytosis pathways are associated with the resilience against Alzheimer’s disease. Transl. Psychiatry 10, 332 (2020).
Berben, L., Floris, G., Wildiers, H. & Hatse, S. Cancer and aging: two tightly interconnected biological processes. Cancers 13, 1400 (2021).
Wyss-Coray, T. Ageing, neurodegeneration and brain rejuvenation. Nature 539, 180–186 (2016).
Childs, B. G. et al. Senescent cells: an emerging target for diseases of ageing. Nat. Rev. Drug. Discov. 16, 718–735 (2017).
Wang, T. W. et al. Blocking PD-L1-PD-1 improves senescence surveillance and ageing phenotypes. Nature 611, 358–364 (2022).
Rosenzweig, N. et al. PD-1/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model. Nat. Commun. 10, 465 (2019).
Tavazoie, M. F. et al. LXR/ApoE activation restricts innate immune suppression in cancer. Cell 172, 825–840 e818 (2018).
Veglia, F., Sanseviero, E. & Gabrilovich, D. I. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat. Rev. Immunol. 21, 485–498 (2021).
Zhan, X. et al. IFN-γ decreased the suppressive function of CD33+HLA-DRlow myeloid cells through down-regulation of PD-1/PD-L2 signaling pathway. Mol. Immunol. 94, 107–120 (2018).
Boulakirba, S. et al. IL-34 and CSF-1 display an equivalent macrophage differentiation ability but a different polarization potential. Sci. Rep. 8, 256 (2018).
Nakajima, S. et al. Neoadjuvant chemotherapy induces IL34 signaling and promotes chemoresistance via tumor-associated macrophage polarization in esophageal squamous cell carcinoma. Mol. Cancer Res. 19, 1085–1095 (2021).
Raggi, C. et al. Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages. J. Hepatol. 66, 102–115 (2017).
Dong, K. et al. FCER1G positively relates to macrophage infiltration in clear cell renal cell carcinoma and contributes to unfavorable prognosis by regulating tumor immunity. BMC Cancer 22, 140 (2022).
Molgora, M. et al. TREM2 modulation remodels the tumor myeloid landscape enhancing anti-PD-1 immunotherapy. Cell 182, 886–900 e817 (2020).
Katzenelenbogen, Y. et al. Coupled scRNA-Seq and intracellular protein activity reveal an immunosuppressive role of TREM2 in cancer. Cell 182, 872–885 e819 (2020).
Yang, T. et al. Platinum-based TREM2 inhibitor suppresses tumors by remodeling the immunosuppressive microenvironment. Angew. Chem. Int. Ed. Engl. 62, e202213337 (2023).
Binnewies, M. et al. Targeting TREM2 on tumor-associated macrophages enhances immunotherapy. Cell Rep. 37, 109844 (2021).
Di Luccia, B. et al. TREM2 deficiency reprograms intestinal macrophages and microbiota to enhance anti-PD-1 tumor immunotherapy. Sci. Immunol. 9, eadi5374 (2024).
Jain, N., Lewis, C. A., Ulrich, J. D. & Holtzman, D. M. Chronic TREM2 activation exacerbates Aβ-associated tau seeding and spreading. J. Exp. Med. 220, e20220654 (2023).
Etxeberria, A. et al. Neutral or detrimental effects of TREM2 agonist antibodies in preclinical models of Alzheimer’s disease and multiple sclerosis. J. Neurosci. 44, e2347232024 (2024).
Wang, S. et al. Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer’s disease model. J. Exp. Med. 217, e20200785 (2020).
Ellwanger, D. C. et al. Prior activation state shapes the microglia response to antihuman TREM2 in a mouse model of Alzheimer’s disease. Proc. Natl Acad. Sci. USA 118, e2017742118 (2021).
Ajith, A. et al. Targeting TREM1 augments antitumor T cell immunity by inhibiting myeloid-derived suppressor cells and restraining anti-PD-1 resistance. J. Clin. Invest. 133, e167951 (2023).
Juric, V. et al. TREM1 activation of myeloid cells promotes antitumor immunity. Sci. Transl. Med. 15, eadd9990 (2023).
Baruah, S. et al. TREM-1 regulates neutrophil chemotaxis by promoting NOX-dependent superoxide production. J. Leukoc. Biol. 105, 1195–1207 (2019).
Boufenzer, A. et al. Potentiation of NETs release is novel characteristic of TREM-1 activation and the pharmacological inhibition of TREM-1 could prevent from the deleterious consequences of NETs release in sepsis. Cell Mol. Immunol. 18, 452–460 (2021).
Colonna, M. The biology of TREM receptors. Nat. Rev. Immunol. 23, 580–594 (2023).
Shi, X., Wei, T., Hu, Y., Wang, M. & Tang, Y. The associations between plasma soluble Trem1 and neurological diseases: a mendelian randomization study. J. Neuroinflammation 19, 218 (2022).
Rodriguez, P. C. et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J. Exp. Med. 202, 931–939 (2005).
Tomic, S. et al. Prostaglanin-E2 potentiates the suppressive functions of human mononuclear myeloid-derived suppressor cells and increases their capacity to expand IL-10-producing regulatory T cell subsets. Front. Immunol. 10, 475 (2019).
Hao, X. et al. Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing. Redox Biol. 56, 102463 (2022).
Yang, L. G., March, Z. M., Stephenson, R. A. & Narayan, P. S. Apolipoprotein E in lipid metabolism and neurodegenerative disease. Trends Endocrinol. Metab. 34, 430–445 (2023).
Hui, B. et al. Inhibition of APOE potentiates immune checkpoint therapy for cancer. Int. J. Biol. Sci. 18, 5230–5240 (2022).
Wu, X. et al. Tumor Apolipoprotein E is a key checkpoint blocking anti-tumor immunity in mouse melanoma. Front. Immunol. 13, 991790 (2022).
Cao, D. Y. et al. ACE overexpression in myeloid cells increases oxidative metabolism and cellular ATP. J. Biol. Chem. 295, 1369–1384 (2020).
Shen, X. Z. et al. Mice with enhanced macrophage angiotensin-converting enzyme are resistant to melanoma. Am. J. Pathol. 170, 2122–2134 (2007).
Zamanian-Daryoush, M. et al. Myeloid-specific genetic ablation of ATP-binding cassette transporter ABCA1 is protective against cancer. Oncotarget 8, 71965–71980 (2017).
Liu, M. et al. Transcription factor c-Maf is a checkpoint that programs macrophages in lung cancer. J. Clin. Invest. 130, 2081–2096 (2020).
Moura Silva, H. et al. c-MAF-dependent perivascular macrophages regulate diet-induced metabolic syndrome. Sci. Immunol. 6, eabg7506 (2021).
Wolf, Y., Anderson, A. C. & Kuchroo, V. K. TIM3 comes of age as an inhibitory receptor. Nat. Rev. Immunol. 20, 173–185 (2020).
Channappanavar, R., Twardy, B. S., Krishna, P. & Suvas, S. Advancing age leads to predominance of inhibitory receptor expressing CD4 T cells. Mech. Ageing Dev. 130, 709–712 (2009).
Latta-Mahieu, M. et al. Systemic immune-checkpoint blockade with anti-PD1 antibodies does not alter cerebral amyloid-β burden in several amyloid transgenic mouse models. Glia 66, 492–504 (2018).
Obst, J., Mancuso, R., Simon, E. & Gomez-Nicola, D. PD-1 deficiency is not sufficient to induce myeloid mobilization to the brain or alter the inflammatory profile during chronic neurodegeneration. Brain Behav. Immun. 73, 708–716 (2018).
Lin, Y. et al. Chronic PD-1 checkpoint blockade does not affect cognition or promote tau clearance in a tauopathy mouse model. Front. Aging Neurosci. 11, 377 (2019).
Kummer, M. P. et al. Microglial PD-1 stimulation by astrocytic PD-L1 suppresses neuroinflammation and Alzheimer’s disease pathology. EMBO J. 40, e108662 (2021).
Xing, Z. et al. Influenza vaccine combined with moderate-dose PD1 blockade reduces amyloid-β accumulation and improves cognition in APP/PS1 mice. Brain Behav. Immun. 91, 128–141 (2021).
Zhao, J. et al. PD-L1/PD-1 checkpoint pathway regulates hippocampal neuronal excitability and learning and memory behavior. Neuron 111, 2709–2726 e2709 (2023).
Zou, Y. et al. Programmed cell death protein 1 blockade reduces glycogen synthase kinase 3β activity and tau hyperphosphorylation in Alzheimer’s disease mouse models. Front. Cell Dev. Biol. 9, 769229 (2021).
van Olst, L. et al. Adaptive immune changes associate with clinical progression of Alzheimer’s disease. Mol. Neurodegener. 19, 38 (2024).
Olingy, C. et al. CD33 expression on peripheral blood monocytes predicts efficacy of anti-PD-1 immunotherapy against non-small cell lung Cancer. Front. Immunol. 13, 842653 (2022).
Bertram, L. et al. Genome-wide association analysis reveals putative Alzheimer’s disease susceptibility loci in addition to APOE. Am. J. Hum. Genet. 83, 623–632 (2008).
Naj, A. C. et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease. Nat. Genet. 43, 436–441 (2011).
Griciuc, A. et al. Alzheimer’s disease risk gene CD33 inhibits microglial uptake of amyloid β. Neuron 78, 631–643 (2013).
Gnoth, K. et al. Evidence for enhanced efficacy of passive immunotherapy against β-amyloid in CD33-negative 5xFAD mice. Biomolecules 12, 399 (2022).
Griciuc, A. et al. TREM2 Acts downstream of CD33 in modulating microglial pathology in Alzheimer’s disease. Neuron 103, 820–835 e827 (2019).
Wang, S. et al. TREM2 drives microglia response to amyloid-β via SYK-dependent and -independent pathways. Cell 185, 4153–4169 e4119 (2022).
Peng, Q. et al. TREM2- and DAP12-dependent activation of PI3K requires DAP10 and is inhibited by SHIP1. Sci. Signal. 3, ra38 (2010).
Taylor, V. C. et al. The myeloid-specific sialic acid-binding receptor, CD33, associates with the protein-tyrosine phosphatases, SHP-1 and SHP-2. J. Biol. Chem. 274, 11505–11512 (1999).
Bhattacherjee, A. et al. The CD33 short isoform is a gain-of-function variant that enhances Aβ(1-42) phagocytosis in microglia. Mol. Neurodegener. 16, 19 (2021).
Eskandari-Sedighi, G. et al. Alzheimer’s disease associated isoforms of human CD33 distinctively modulate microglial cell responses in 5XFAD mice. Mol. Neurodegener. 19, 42 (2024).
Bhattacherjee, A. et al. Increasing phagocytosis of microglia by targeting CD33 with liposomes displaying glycan ligands. J. Control. Release 338, 680–693 (2021).
de Mingo Pulido, A. et al. The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake. Immunity 54, 1154–1167 e1157 (2021).
Sakuishi, K. et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 207, 2187–2194 (2010).
Butovsky, O. & Weiner, H. L. Microglial signatures and their role in health and disease. Nat. Rev. Neurosci. 19, 622–635 (2018).
Colonna, M. & Butovsky, O. Microglia function in the central nervous system during health and neurodegeneration. Annu. Rev. Immunol. 35, 441–468 (2017).
Badimon, A. et al. Negative feedback control of neuronal activity by microglia. Nature 586, 417–423 (2020).
Bawa, K. K. et al. A peripheral neutrophil-related inflammatory factor predicts a decline in executive function in mild Alzheimer’s disease. J. Neuroinflammation 17, 84 (2020).
Farrer, L. A. et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278, 1349–1356 (1997).
Corder, E. H. et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261, 921–923 (1993).
Strittmatter, W. J. et al. Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl Acad. Sci. USA 90, 1977–1981 (1993).
Raber, J. et al. Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females. Proc. Natl Acad. Sci. USA 95, 10914–10919 (1998).
Youmans, K. L. et al. APOE4-specific changes in Aβ accumulation in a new transgenic mouse model of Alzheimer disease. J. Biol. Chem. 287, 41774–41786 (2012).
Liu, S. et al. The host shapes the gut microbiota via fecal MicroRNA. Cell Host Microbe 19, 32–43 (2016).
Parhizkar, S. et al. Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE. Nat. Neurosci. 22, 191–204 (2019).
Ulland, T. K. et al. TREM2 maintains microglial metabolic fitness in Alzheimer’s disease. Cell 170, 649–663 e613 (2017).
Wang, Y. et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer’s disease model. Cell 160, 1061–1071 (2015).
Margeta, M. A. et al. Apolipoprotein E4 impairs the response of neurodegenerative retinal microglia and prevents neuronal loss in glaucoma. Immunity 55, 1627–1644 e1627 (2022).
Lund, H. et al. Fatal demyelinating disease is induced by monocyte-derived macrophages in the absence of TGF-β signaling. Nat. Immunol. 19, 1–7 (2018).
Yang, R. et al. Fc Fragment of IgE Receptor Ig (FCER1G) acts as a key gene involved in cancer immune infiltration and tumour microenvironment. Immunology 168, 302–319 (2023).
Chen, H. M. et al. Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity. J. Clin. Invest. 128, 5647–5662 (2018).
Zhao, P. et al. LILRB2-mediated TREM2 signaling inhibition suppresses microglia functions. Mol. Neurodegener. 17, 44 (2022).
Zhang, W. Y., Gaynor, P. M. & Kruth, H. S. Apolipoprotein E produced by human monocyte-derived macrophages mediates cholesterol efflux that occurs in the absence of added cholesterol acceptors. J. Biol. Chem. 271, 28641–28646 (1996).
Tenger, C. & Zhou, X. Apolipoprotein E modulates immune activation by acting on the antigen-presenting cell. Immunology 109, 392–397 (2003).
Bonacina, F. et al. Myeloid apolipoprotein E controls dendritic cell antigen presentation and T cell activation. Nat. Commun. 9, 3083 (2018).
Liu, C. C. et al. Cell-autonomous effects of APOE4 in restricting microglial response in brain homeostasis and Alzheimer’s disease. Nat. Immunol. 24, 1854–1866 (2023).
Qi, G. et al. ApoE4 impairs neuron-astrocyte coupling of fatty acid metabolism. Cell Rep. 34, 108572 (2021).
Brosseron, F. et al. Interrelations of Alzheimer s disease candidate biomarkers neurogranin, fatty acid-binding protein 3 and ferritin to neurodegeneration and neuroinflammation. J. Neurochem. 157, 2210–2224 (2021).
Jay, T. R. et al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer’s disease mouse models. J. Exp. Med. 212, 287–295 (2015).
Leyns, C. E. G. et al. TREM2 function impedes tau seeding in neuritic plaques. Nat. Neurosci. 22, 1217–1222 (2019).
Siddiqui, A. A. et al. Cathepsin B promotes Aβ proteotoxicity by modulating aging regulating mechanisms. Nat. Commun. 15, 8564 (2024).
Efthymiou, A. G. & Goate, A. M. Late onset Alzheimer’s disease genetics implicates microglial pathways in disease risk. Mol. Neurodegener. 12, 43 (2017).
Zhang, C. et al. MS4A6A is a new prognostic biomarker produced by macrophages in glioma patients. Front. Immunol. 13, 865020 (2022).
de Majo, M. et al. Granulin loss of function in human mature brain organoids implicates astrocytes in TDP-43 pathology. Stem Cell Rep. 18, 706–719 (2023).
Götzl, J. K. et al. Opposite microglial activation stages upon loss of PGRN or TREM2 result in reduced cerebral glucose metabolism. EMBO Mol. Med. 11, e9711 (2019).
Minami, S. S. et al. Progranulin protects against amyloid β deposition and toxicity in Alzheimer’s disease mouse models. Nat. Med. 20, 1157–1164 (2014).
Rhinn, H., Tatton, N., McCaughey, S., Kurnellas, M. & Rosenthal, A. Progranulin as a therapeutic target in neurodegenerative diseases. Trends Pharmacol. Sci. 43, 641–652 (2022).
Suarez-Calvet, M. et al. CSF progranulin increases in the course of Alzheimer’s disease and is associated with sTREM2, neurodegeneration and cognitive decline. EMBO Mol. Med. 10, e9712 (2018).
Huang, J. et al. Blood levels of MCP-1 modulate the genetic risks of Alzheimer’s disease mediated by HLA-DRB1 and APOE for Alzheimer’s disease. Alzheimers Dement. 19, 1925–1937 (2023).
Verschoor, C. P. et al. Blood CD33+HLA-DR− myeloid-derived suppressor cells are increased with age and a history of cancer. J. Leukoc. Biol. 93, 633–637 (2013).
Gu, Y. et al. RhoH GTPase recruits and activates Zap70 required for T cell receptor signaling and thymocyte development. Nat. Immunol. 7, 1182–1190 (2006).
Katsuyama, T., Li, H., Krishfield, S. M., Kyttaris, V. C. & Moulton, V. R. Splicing factor SRSF1 limits IFN-γ production via RhoH and ameliorates experimental nephritis. Rheumatology 60, 420–429 (2021).
Hall, J. A. et al. Transcription factor RORalpha enforces stability of the TH17 cell effector program by binding to a Rorc cis-regulatory element. Immunity 55, 2027–2043 e2029 (2022).
Cornely, R. et al. Annexin A6 regulates interleukin-2-mediated T-cell proliferation. Immunol. Cell Biol. 94, 543–553 (2016).
Enrich, C. et al. Annexin A6-Linking Ca2+ signaling with cholesterol transport. Biochim. Biophys. Acta 1813, 935–947 (2011).
Baggen, J. et al. TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry. Cell 186, 3427–3442 e3422 (2023).
Lee, J. Y. et al. The major TMEM106B dementia risk allele affects TMEM106B protein levels, fibril formation, and myelin lipid homeostasis in the ageing human hippocampus. Mol. Neurodegener. 18, 63 (2023).
Thomas, R. M. et al. Foxp3 depends on Ikaros for control of regulatory T cell gene expression and function. eLife 12, e91392 (2024).
Fazeli, E. et al. A familial missense variant in the Alzheimer’s disease gene SORL1 impairs its maturation and endosomal sorting. Acta Neuropathol. 147, 20 (2024).
Chen, H. M. et al. Neutrophils and monocytes express high levels of PU.1 (Spi-1) but not Spi-B. Blood 85, 2918–2928 (1995).
Anderson, K. L., Smith, K. A., Pio, F., Torbett, B. E. & Maki, R. A. Neutrophils deficient in PU.1 do not terminally differentiate or become functionally competent. Blood 92, 1576–1585 (1998).
Wang, J., Shiratori, I., Uehori, J., Ikawa, M. & Arase, H. Neutrophil infiltration during inflammation is regulated by PILRalpha via modulation of integrin activation. Nat. Immunol. 14, 34–40 (2013).
Grieshaber-Bouyer, R. et al. The neutrotime transcriptional signature defines a single continuum of neutrophils across biological compartments. Nat. Commun. 12, 2856 (2021).
van Eck, M. et al. Leukocyte ABCA1 controls susceptibility to atherosclerosis and macrophage recruitment into tissues. Proc. Natl Acad. Sci. USA 99, 6298–6303 (2002).
Yalcinkaya, M. et al. Cholesterol accumulation in macrophages drives NETosis in atherosclerotic plaques via IL-1β secretion. Cardiovasc. Res. 119, 969–981 (2023).
Cunin, P. et al. Clusterin facilitates apoptotic cell clearance and prevents apoptotic cell-induced autoimmune responses. Cell Death Dis. 7, e2215 (2016).
Ishikawa, Y. et al. Role of the clathrin adaptor PICALM in normal hematopoiesis and polycythemia vera pathophysiology. Haematologica 100, 439–451 (2015).
Swanson, B. J., Jack, H. M. & Lyons, G. E. Characterization of myocyte enhancer factor 2 (MEF2) expression in B and T cells: MEF2C is a B cell-restricted transcription factor in lymphocytes. Mol. Immunol. 35, 445–458 (1998).
Khiem, D., Cyster, J. G., Schwarz, J. J. & Black, B. L. A p38 MAPK-MEF2C pathway regulates B-cell proliferation. Proc. Natl Acad. Sci. USA 105, 17067–17072 (2008).
Wilker, P. R. et al. Transcription factor Mef2c is required for B cell proliferation and survival after antigen receptor stimulation. Nat. Immunol. 9, 603–612 (2008).
Stehling-Sun, S., Dade, J., Nutt, S. L., DeKoter, R. P. & Camargo, F. D. Regulation of lymphoid versus myeloid fate ‘choice’ by the transcription factor Mef2c. Nat. Immunol. 10, 289–296 (2009).
Pappu, R. et al. Requirement for B cell linker protein (BLNK) in B cell development. Science 286, 1949–1954 (1999).
Minegishi, Y. et al. An essential role for BLNK in human B cell development. Science 286, 1954–1957 (1999).
Chen, Z. et al. Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. Nature 521, 357–361 (2015).
Olufunmilayo, E. O. & Holsinger, R. M. D. INPP5D/SHIP1: expression, regulation and roles in Alzheimer’s disease pathophysiology. Genes 14, 1845 (2023).
de Rooij, M. F. M. et al. A loss-of-adhesion CRISPR–Cas9 screening platform to identify cell adhesion-regulatory proteins and signaling pathways. Nat. Commun. 13, 2136 (2022).
Guinamard, R., Okigaki, M., Schlessinger, J. & Ravetch, J. V. Absence of marginal zone B cells in Pyk-2-deficient mice defines their role in the humoral response. Nat. Immunol. 1, 31–36 (2000).
Xu, B. et al. Comprehensive analysis of hub biomarkers associated with immune and oxidative stress in Hashimoto’s thyroiditis. Arch. Biochem. Biophys. 745, 109713 (2023).
Kremer, A. N. et al. Development of a coordinated allo T cell and auto B cell response against autosomal PTK2B after allogeneic hematopoietic stem cell transplantation. Haematologica 99, 365–369 (2014).
Milili, M. et al. A new case of autosomal recessive aγglobulinaemia with impaired pre-B cell differentiation due to a large deletion of the IGH locus. Eur. J. Pediatr. 161, 479–484 (2002).
Schoenaker, M. H. D. et al. Immunodeficiency in Bloom’s syndrome. J. Clin. Immunol. 38, 35–44 (2018).
Gunasekaran, M. et al. Immunization elicits antigen-specific antibody sequestration in dorsal root ganglia sensory neurons. Front. Immunol. 9, 638 (2018).
Hata, A. et al. Differential gene analysis during the development of obliterative bronchiolitis in a murine orthotopic lung transplantation model: a comprehensive transcriptome-based analysis. PLoS ONE 15, e0232884 (2020).
Anderson, A. C., Joller, N. & Kuchroo, V. K. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity 44, 989–1004 (2016).
Gleason, M. K. et al. Tim-3 is an inducible human natural killer cell receptor that enhances interferon γ production in response to galectin-9. Blood 119, 3064–3072 (2012).
Ndhlovu, L. C. et al. Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood 119, 3734–3743 (2012).
So, E. C. et al. NK cell expression of Tim-3: first impressions matter. Immunobiology 224, 362–370 (2019).
Yang, C. et al. Heterogeneity of human bone marrow and blood natural killer cells defined by single-cell transcriptome. Nat. Commun. 10, 3931 (2019).
Mazzurana, L. et al. Suppression of Aiolos and Ikaros expression by lenalidomide reduces human ILC3-ILC1/NK cell transdifferentiation. Eur. J. Immunol. 49, 1344–1355 (2019).
Liu, J. et al. Tcf1 sustains the expression of multiple regulators in promoting early natural killer cell development. Front. Immunol. 12, 791220 (2021).
Sun, A. et al. Comprehensive pan-cancer investigation: unraveling the oncogenic, prognostic, and immunological significance of Abelson interactor family member 3 gene in human malignancies. Front. Mol. Biosci. 10, 1277830 (2023).
Cho, Y. E. et al. Circulating immune cell landscape in patients who had mild ischaemic stroke. Stroke Vasc. Neurol. 7, 319–327 (2022).
Ebrahimian, T. et al. Absence of four-and-a-half LIM domain protein 2 decreases atherosclerosis in ApoE−/− mice. Arterioscler. Thromb. Vasc. Biol. 35, 1190–1197 (2015).
Kurakula, K. et al. The LIM-only protein FHL2 reduces vascular lesion formation involving inhibition of proliferation and migration of smooth muscle cells. PLoS ONE 9, e94931 (2014).
Dong, S. et al. Estrogen-like activity and dual roles in cell signaling of an agaricus blazei murrill mycelia-dikaryon extract. Microbiol. Res. 167, 231–237 (2012).
Lee, M. Y. et al. Genomic changes in regenerated porcine coronary arterial endothelial cells. Arterioscler. Thromb. Vasc. Biol. 27, 2443–2449 (2007).
Schrimpf, C. et al. Pericyte TIMP3 and ADAMTS1 modulate vascular stability after kidney injury. J. Am. Soc. Nephrol. 23, 868–883 (2012).
Lee, N. V. et al. ADAMTS1 mediates the release of antiangiogenic polypeptides from TSP1 and 2. EMBO J. 25, 5270–5283 (2006).
Jin, Y. et al. Identification and validation of potential hypoxia-related genes associated with coronary artery disease. Front. Physiol. 14, 1181510 (2023).
Spencer, H. L. et al. Role of TPBG (trophoblast glycoprotein) antigen in human pericyte migratory and angiogenic activity. Arterioscler. Thromb. Vasc. Biol. 39, 1113–1124 (2019).
Zhou, Z. et al. The cerebral cavernous malformation pathway controls cardiac development via regulation of endocardial MEKK3 signaling and KLF expression. Dev. Cell 32, 168–180 (2015).
Richards, J. S. et al. Regulated expression of ADAMTS family members in follicles and cumulus oocyte complexes: evidence for specific and redundant patterns during ovulation. Biol. Reprod. 72, 1241–1255 (2005).
Diet, F. et al. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 94, 2756–2767 (1996).
Urata, H. et al. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J. Clin. Invest. 91, 1269–1281 (1993).
Ren, X. et al. FOXF1 transcription factor is required for formation of embryonic vasculature by regulating VEGF signaling in endothelial cells. Circ. Res. 115, 709–720 (2014).
Cai, Y. et al. FOXF1 maintains endothelial barrier function and prevents edema after lung injury. Sci. Signal. 9, ra40 (2016).
Kunkle, B. W. et al. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nat. Genet. 51, 414–430 (2019).
Lambert, J. C. et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat. Genet. 45, 1452–1458 (2013).
Novikova, G. et al. Integration of Alzheimer’s disease genetics and myeloid genomics identifies disease risk regulatory elements and genes. Nat. Commun. 12, 1610 (2021).
Tansey, K. E., Cameron, D. & Hill, M. J. Genetic risk for Alzheimer’s disease is concentrated in specific macrophage and microglial transcriptional networks. Genome Med. 10, 14 (2018).
Uhlen, M. et al. A genome-wide transcriptomic analysis of protein-coding genes in human blood cells. Science 366, eaax9198 (2019).
Targa Dias Anastacio, H., Matosin, N. & Ooi, L. Neuronal hyperexcitability in Alzheimer’s disease: what are the drivers behind this aberrant phenotype? Transl. Psychiatry 12, 257 (2022).
Zoghbi, H. Y. & Bear, M. F. Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities. Cold Spring Harb. Perspect. Biol. 4, a009886 (2012).
Kemp, S. B. et al. Apolipoprotein E promotes immune suppression in pancreatic cancer through NF-kappaB-mediated production of CXCL1. Cancer Res. 81, 4305–4318 (2021).
Forconi, C. S. et al. A new hope for CD56(neg)CD16(pos) NK cells as unconventional cytotoxic mediators: an adaptation to chronic diseases. Front. Cell Infect. Microbiol. 10, 162 (2020).
Zhou, T. et al. PGRN inhibits CD8+ T cell recruitment and promotes breast cancer progression by up-regulating ICAM-1 on TAM. Cancer Immunol. Immunother. 73, 76 (2024).
Pillay, J., Tak, T., Kamp, V. M. & Koenderman, L. Immune suppression by neutrophils and granulocytic myeloid-derived suppressor cells: similarities and differences. Cell Mol. Life Sci. 70, 3813–3827 (2013).
McGeachy, M. J. et al. TGF-β and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain TH17 cell-mediated pathology. Nat. Immunol. 8, 1390–1397 (2007).
Hayek, D. et al. Different inflammatory signatures based on CSF biomarkers relate to preserved or diminished brain structure and cognition. Mol. Psychiatry 29, 992–1004 (2024).
Luo, J., Thomassen, J. Q., Nordestgaard, B. G., Tybjaerg-Hansen, A. & Frikke-Schmidt, R. Blood leukocyte counts in Alzheimer disease. JAMA Netw. Open. 5, e2235648 (2022).
Mehta, N. H. et al. Peripheral immune cell imbalance is associated with cortical β-amyloid deposition and longitudinal cognitive decline. Sci. Rep. 13, 8847 (2023).
Kuyumcu, M. E. et al. The evaluation of neutrophil–lymphocyte ratio in Alzheimer’s disease. Dement. Geriatr. Cogn. Disord. 34, 69–74 (2012).
Rembach, A. et al. An increased neutrophil–lymphocyte ratio in Alzheimer’s disease is a function of age and is weakly correlated with neocortical amyloid accumulation. J. Neuroimmunol. 273, 65–71 (2014).
Jacobs, T. et al. The neutrophil to lymphocyte ratio associates with markers of Alzheimer’s disease pathology in cognitively unimpaired elderly people. Immun. Ageing 21, 32 (2024).
Wu, C. Y. et al. Neutrophil activation in Alzheimer’s disease and mild cognitive impairment: a systematic review and meta-analysis of protein markers in blood and cerebrospinal fluid. Ageing Res. Rev. 62, 101130 (2020).
Gudden, J., Arias Vasquez, A. & Bloemendaal, M. The effects of intermittent fasting on brain and cognitive function. Nutrients 13, 3166 (2021).
Holec, A. D., Mandal, S., Prathipati, P. K. & Destache, C. J. Nucleotide reverse transcriptase inhibitors: a thorough review, present status and future perspective as HIV therapeutics. Curr. Hiv. Res. 15, 411–421 (2017).
Wahl, D., Grant, R. A. & LaRocca, T. J. The reverse transcriptase inhibitor 3TC modulates hippocampal transcriptome signatures of inflammation in tauopathy model mice. Exp. Gerontol. 192, 112458 (2024).
Wahl, D. et al. The reverse transcriptase inhibitor 3TC protects against age-related cognitive dysfunction. Aging Cell 22, e13798 (2023).
Duggan, M. R. et al. Immune modulation to treat Alzheimer’s disease. Mol. Neurodegener. 20, 39 (2025).
Magagnoli, J. et al. Association of nucleoside reverse transcriptase inhibitor use with reduced risk of Alzheimer’s disease risk. Alzheimers Dement. 21, e70180 (2025).
Valles-Saiz, L., Avila, J. & Hernandez, F. Lamivudine (3TC), a nucleoside reverse transcriptase inhibitor, prevents the neuropathological alterations present in mutant tau transgenic mice. Int. J. Mol. Sci. 24, 11144 (2023).
Ramirez, P. et al. Pathogenic tau accelerates aging-associated activation of transposable elements in the mouse central nervous system. Prog. Neurobiol. 208, 102181 (2022).
Ramirez, P. et al. Nanopore-based DNA long-read sequencing analysis of the aged human brain. Preprint at bioRxiv https://doi.org/10.1101/2024.02.01.578450 (2024).
Rueda, N. et al. Anti-IL17 treatment ameliorates down syndrome phenotypes in mice. Brain Behav. Immun. 73, 235–251 (2018).
Baek, H. et al. Neuroprotective effects of CD4+CD25+Foxp3+ regulatory T cells in a 3xTg-AD Alzheimer’s disease model. Oncotarget 7, 69347–69357 (2016).
Faridar, A. et al. Restoring regulatory T-cell dysfunction in Alzheimer’s disease through ex vivo expansion. Brain Commun. 2, fcaa112 (2020).
Ciccocioppo, F. et al. The characterization of regulatory T-cell profiles in Alzheimer’s disease and multiple sclerosis. Sci. Rep. 9, 8788 (2019).
Lopes, J. R. et al. Nasal administration of anti-CD3 monoclonal antibody ameliorates disease in a mouse model of Alzheimer’s disease. Proc. Natl Acad. Sci. USA 120, e2309221120 (2023).
Faridar, A. et al. A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer’s disease. Transl. Neurodegener. 12, 54 (2023).
Frenkel, D. et al. A nasal proteosome adjuvant activates microglia and prevents amyloid deposition. Ann. Neurol. 63, 591–601 (2008).
Michaud, J. P. et al. Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid a improves Alzheimer’s disease-related pathology. Proc. Natl Acad. Sci. USA 110, 1941–1946 (2013).
Frenkel, D. et al. Scara1 deficiency impairs clearance of soluble amyloid-β by mononuclear phagocytes and accelerates Alzheimer’s-like disease progression. Nat. Commun. 4, 2030 (2013).
Harach, T. et al. Reduction of Aβ amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota. Sci. Rep. 7, 41802 (2017).
Minter, M. R. et al. Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer’s disease. Sci. Rep. 6, 30028 (2016).
Kim, N. et al. Transplantation of gut microbiota derived from Alzheimer’s disease mouse model impairs memory function and neurogenesis in C57BL/6 mice. Brain Behav. Immun. 98, 357–365 (2021).
Cattaneo, A. et al. Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. Neurobiol. Aging 49, 60–68 (2017).
Wasen, C. et al. Bacteroidota inhibit microglia clearance of amyloid-β and promote plaque deposition in Alzheimer’s disease mouse models. Nat. Commun. 15, 3872 (2024).
Hazan, S. Rapid improvement in Alzheimer’s disease symptoms following fecal microbiota transplantation: a case report. J. Int. Med. Res. 48, 300060520925930 (2020).
Park, S. H. et al. Cognitive function improvement after fecal microbiota transplantation in Alzheimer’s dementia patient: a case report. Curr. Med. Res. Opin. 37, 1739–1744 (2021).
Park, S. H. et al. Fecal microbiota transplantation can improve cognition in patients with cognitive decline and Clostridioides difficile infection. Aging 14, 6449–6466 (2022).
